reports
Valneva Announces Health Canada Approval of the World’s First Chikungu...
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ® Saint-Herblain (France), June 24, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) also rec...
Corbion reports the progress of its € 20 million share buyback program...
Corbion reports the progress of its € 20 million share buyback program 17 June – 21 June 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 17 June up to and including 21 June 2024 a total of 108,295 shares were repurchased at an average price of €19.0185 for a total amount of €2,059,605.14. To date, the total consideration for shares repurchased amounts to €14,813,411.83 representing 74.07% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overvie...
- Bruno Bulic
- Oscar Haffen Lamm
Chikungunya vaccine competitor progressing in-line
Good to know: Bavarian yesterday announced that it completed its Biologic License Application (BLA) with the US FDA for its Chikungunya vaccine CHIKV VLP. Bavarian Nordic’s CHIKV might thus enter the market in H1 2025 if approved by the FDA. We believe the news largely anticipated by the market and
Corbion reports the progress of its € 20 million share buyback program...
Corbion reports the progress of its € 20 million share buyback program 10 June – 14 June 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 10 June up to and including 14 June 2024 a total of 99,456 shares were repurchased at an average price of €19.6238 for a total amount of €1,951,701.22. To date, the total consideration for shares repurchased amounts to €12,753,806.69 representing 63.77% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of...
- Bruno Cavalier
- Jean-Baptiste Rouphael
- Luis de Toledo Heras
- Thomas Zlowodzki
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 10/06/2024
En ligne avec les sondages, les élections au Parlement européen ont abouti à la déroute de la liste macroniste (14.5% des voix), loin derrière le Rassemblement national (31.5%). En réaction, le président français a dissous l’Assemblée nationale. Ce droit n’avait pas été exercé depuis 1997. Des élections anticipées auront lieu les 30 juin et 7 juillet. Dans une campagne extrêmement courte, tout laisse à croire que le RN sera le premier parti de la future Assemblée. En toute logique, le...
- Jean-Baptiste Rouphael
- Luis de Toledo Heras
- Thomas Zlowodzki
- Yan Derocles
- Luis de Toledo Heras
Navigator : Upgrading to Neutral on better risk-reward proposition and...
>Integrating recent acquisition in the UK’s tissue market - We are updating our estimates on Navigator after the successful acquisition of Accrol in the UK (one of the leading independent tissue converters for € 152m, 5% of the group’s market cap) with estimated sales of € 240m in 2024 (c.11% of Navigator’s 2024e sales). The transaction (EV of € c.220m, 9x EV/EBITDA LTM) strengthens its position in the attractive tissue market in Western Europe, particularly to the pr...
Corbion reports the progress of its € 20 million share buyback program...
Corbion reports the progress of its € 20 million share buyback program 3 June – 7 June 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 3 June up to and including 7 June 2024 a total of 110,083 shares were repurchased at an average price of €20.1621 for a total amount of €2,219,505.58. To date, the total consideration for shares repurchased amounts to €10,802,105.47 representing 54.01% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of...
- Jeremy Garnier
ODDO : ODDO BHF Nextcap Forum: Feedback from day three
>Feedback from 52 companies present on day three - Our 13th edition of the ODDO BHF Nextcap Forum takes place on June 4 and 5 in Paris, and on June 6 virtually. Following the third day, which took place yesterday virtually at our Paris office with 52 companies in attendance, we publish hereafter feedback for those companies present:Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcPhy EnergyAltriMister SpexAtresmediaNein...
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
FGA FIGEAC AERO SA
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
SRP SRP GROUPE SA
AUB AUBAY SA
NTG NETGEM SA
VLS VALNEVA SE
LNA LNA SANTE SA
KOF KAUFMAN & BROAD SA
FNAC FNAC DARTY SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BAMNB KONINKLIJKE BAM GROEP NV
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
GREEN GREENYARD NV
MCPHY MCPHY ENERGY SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ENC ENCE ENERGIA Y CELULOSA SA
LTA ALTAMIR ACT PORTEUR
INSD VERIMATRIX SA
SIFG SIF HOLDING NV
LRE LAR ESPANA REAL ESTATE SOCIMI SA
VLTSA VOLTALIA
HBH HORNBACH HOLDING AG & CO. KGAA
FFARM FORFARMERS
TRE TECNICAS REUNIDAS SA
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
HOME NEINOR HOMES SA
MDM MAISONS DU MONDE SA
SMCP SMCP SA
AVTX AVANTIUM NV
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALKAL KALRAY SA
AEDAS AEDAS HOMES SA
WAVE WAVESTONE SA
GRE GRENERGY RENOVABLES
THEP THERMADOR HOLDING SA
ALCUR ARCURE SA
TOM2 TOMTOM NV
CLA CLARANOVA SE
S30 SOLUTIONS 30 SE
ZEL PHARMA MAR SA
SOL SOLTEC POWER HOLDINGS
BLV BELIEVE SA
MRX MISTER SPEX SE
ALAFY AFYREN
FORSE FORSEE POWER SA
HDF HYDROGENE DE FRANCE
ALVGO VOGO SA
WAGA WAGA ENERGY SA
ALHAF HAFFNER ENERGY SA
EAPI EUROAPI
GVOLT GREENVOLT - ENERGIAS RENOVAVEIS S.A.
LHYFE LHYFE S.A.
- Jeremy Garnier
ODDO : ODDO BHF Nextcap Forum : Feedbacks 3ème journée
>Feedback de 52 sociétés présentes le 3ème jour - Notre 13ème édition du ODDO BHF Nextcap Forum a lieu les 4 et 5 juin en physique à Paris et le 6 juin en virtuel. Suite à la troisième journée qui a eu lieu hier en virtuel avec 53 de sociétés présentes, nous publions ci-après un feedback pour chacune des sociétés couvertes :Aedas HomesLhyfeAfyrenMaisons Du MondeAltamirMcphy EnergyAltriMister SpexAtresmediaNeinor Homes§...
TNG TRANSGENE SA
INF INFOTEL SA
FGA FIGEAC AERO SA
BLC BASTIDE LE CONFORT MEDICAL SA
KCO KLOECKNER & CO SE
ALTR ALTRI SGPS SA
SWP SWORD GROUP SE
SRP SRP GROUPE SA
AUB AUBAY SA
NTG NETGEM SA
VLS VALNEVA SE
LNA LNA SANTE SA
KOF KAUFMAN & BROAD SA
FNAC FNAC DARTY SA
BVB BORUSSIA DORTMUND GMBH & CO. KGAA
BAMNB KONINKLIJKE BAM GROEP NV
IDIP INSTITUT DE DEVELOPPEMENT INDUSTRIEL SCA
GREEN GREENYARD NV
MCPHY MCPHY ENERGY SA
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
ENC ENCE ENERGIA Y CELULOSA SA
LTA ALTAMIR ACT PORTEUR
INSD VERIMATRIX SA
SIFG SIF HOLDING NV
LRE LAR ESPANA REAL ESTATE SOCIMI SA
VLTSA VOLTALIA
HBH HORNBACH HOLDING AG & CO. KGAA
FFARM FORFARMERS
TRE TECNICAS REUNIDAS SA
PSG PROSEGUR COMPANIA DE SEGURIDAD SA
HOME NEINOR HOMES SA
MDM MAISONS DU MONDE SA
SMCP SMCP SA
AVTX AVANTIUM NV
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALKAL KALRAY SA
AEDAS AEDAS HOMES SA
WAVE WAVESTONE SA
GRE GRENERGY RENOVABLES
THEP THERMADOR HOLDING SA
ALCUR ARCURE SA
TOM2 TOMTOM NV
CLA CLARANOVA SE
S30 SOLUTIONS 30 SE
ZEL PHARMA MAR SA
SOL SOLTEC POWER HOLDINGS
BLV BELIEVE SA
MRX MISTER SPEX SE
ALAFY AFYREN
FORSE FORSEE POWER SA
ALVGO VOGO SA
WAGA WAGA ENERGY SA
ALHAF HAFFNER ENERGY SA
EAPI EUROAPI
GVOLT GREENVOLT - ENERGIAS RENOVAVEIS S.A.
LHYFE LHYFE S.A.
Valneva annonce la mise à disposition des documents préparatoires à so...
Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction Saint-Herblain (France), 5 juin 2024 – (Nasdaq : VALN ; Euronext Paris : VLA) (la « Société »), société spécialisée dans les vaccins, a annoncé aujourd’hui la mise à disposition des documents préparatoires à son Assemblée Générale Mixte (l’« Assemblée ») qui se tiendra le 26 juin 2024, à 14 heures, à l’hôtel Sofitel Lyon Bellecour, 20 quai du Docteur Gailleton, 69002 Lyon. L’avis préalable de réunion – comportant l’ordre du jour, les projets de r...
Valneva Announces Availability of Documentation for its Combined Share...
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update Saint-Herblain (France), June 5, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and ins...
VALNEVA - Declaration of shares and voting rights: May 31, 2024
VALNEVA - Declaration of shares and voting rights: May 31, 2024 VALNEVA Declaration of shares and voting rights May 31, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 4, 2024 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of votin...
Valneva to Present and Hold Investor Meetings at Upcoming Conferences ...
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June Saint-Herblain (France), June 4, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024. Valneva will present and meet with global institutional investors to discuss VLA15, the world’s leading Lyme Disease vaccine candidate, in Phase 3 development and partnered with Pfizer; the Company’s growing commercial business, including ongoing launch plans for IXCHIQ®...
Valneva annonce sa participation à différentes conférences investisseu...
Valneva annonce sa participation à différentes conférences investisseurs du mois de juin Saint-Herblain (France), le 4 juin 2024 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, annonce aujourd’hui que des membres de son équipe dirigeante participeront à différentes conférences d’investisseurs aux États-Unis et en Europe au cours du mois de juin 2024. Valneva fera des présentations et rencontrera des investisseurs institutionnels internationaux pour échanger sur VLA15, le candidat vaccin contre la maladie de Lyme le plus avancé au monde, en Phase 3 de développe...
- Bruno Bulic
- Oscar Haffen Lamm
Valneva positive safety update on growth driver VLA15
Valneva confirms good safety and tolerability of its Lyme disease vaccine VLA15. Company already presented in 2021 top-line data for those VLA15 Ph. II studies, detailed analysis now published in Lancet. On the efficacy front, nearly full seroconversion has been presented earlier (ph. III underway,
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the La...
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases Saint-Herblain (France), June 3, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, ‘Vaccine Against Lyme for Outdoor Recreationists’ (VALOR). Juan Carlos...
Valneva annonce la publication de deux essais de Phase 2 sur la maladi...
Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases Saint-Herblain (France), 3 juin 2024 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que les résultats de deux essais cliniques de Phase 2 sur le candidat vaccin contre la maladie de Lyme, VLA15, ont été publiés dans la revue médicale Lancet Infectious Diseases. Ces essais, ainsi qu’un troisième essai de Phase 2 chez des participants pédiatriques, ont soutenu la conception de l'essai pivot de Phase 3 en cours, « Vaccine Aga...
EQS-News: Schaeffler appoints new Head of Investor Relations
EQS-News: Schaeffler AG / Key word(s): Personnel Schaeffler appoints new Head of Investor Relations 03.06.2024 / 11:06 CET/CEST The issuer is solely responsible for the content of this announcement. Schaeffler appoints new Head of Investor Relations Vitesco Technologies’ Heiko Eber appointed as Head of Investor Relations (IR) at Schaeffler Renata Casaro to lead newly created Global Risk & Macroeconomic Analysis unit Head of IR to report to Schaeffler CFO, Head of Global Risk & Macroeconomic Analysis to report to CEO Herzogenaurach | June 3, 2024 | Schaeffler AG annou...
EQS-News: Schaeffler ernennt neuen Leiter für Investor Relations
EQS-News: Schaeffler AG / Schlagwort(e): Personalie Schaeffler ernennt neuen Leiter für Investor Relations 03.06.2024 / 11:06 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Schaeffler ernennt neuen Leiter für Investor Relations Heiko Eber von Vitesco Technologies wird neuer Leiter Investor Relations (IR) bei Schaeffler Renata Casaro wird Leiterin der neu geschaffenen Abteilung Global Risk & Macroeconomic Analysis Die Leitung IR berichtet an den Finanzvorstand (CFO) von Schaeffler, die Leitung Global Risk & Macroeconomic Analysis ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.